Abstract:The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due to its potentially superior effects compared with protein inhibition. Recent advancements in the biotech and pharmaceutical sectors have led to the development of compounds that are currently in human trials, with some showing promising clinical results. However, the use of computational tools in TPD is still limited, as it has distinct characteristics compared with traditional computational drug design methods. TPD involves creating a ternary structure (protein-degrader-ligase) responsible for the biological function, such as ubiquitination and subsequent proteasomal degradation, which depends on the spatial orientation of the protein of interest (POI) relative to E2-loaded ubiquitin. Modeling this structure necessitates a unique blend of tools initially developed for small molecules (e.g., docking) and biologics (e.g., protein-protein interaction modeling). Additionally, degrader molecules, particularly heterobifunctional degraders, are generally larger than conventional small molecule drugs, leading to challenges in determining drug-like properties like solubility and permeability. Furthermore, the catalytic nature of TPD makes occupancy-based modeling insufficient. TPD consists of multiple interconnected yet distinct steps, such as POI binding, E3 ligase binding, ternary structure interactions, ubiquitination, and degradation, along with traditional small molecule properties. A comprehensive set of tools is needed to address the dynamic nature of the induced proximity ternary complex and its implications for ubiquitination. In this Perspective, we discuss the current state of computational tools for TPD. We start by describing the series of steps involved in the degradation process and the experimental methods used to characterize them. Then, we delve into a detailed analysis of the computational tools employed in TPD. We also present an integrative approach that has proven successful for degrader design and its impact on project decisions. Finally, we examine the future prospects of computational methods in TPD and the areas with the greatest potential for impact.

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Recent advances in targeted protein degraders as potential therapeutic agents

Targeted protein degradation in drug development: Recent advances and future challenges

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective

Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules

Targeted protein degradation: mechanisms, strategies and application

Targeted protein degradation: expanding the toolbox

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Novel approaches to targeted protein degradation technologies in drug discovery

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Discovery of E3 Ligase Ligands for Target Protein Degradation

Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods

Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs

Targeted protein degradation directly engaging lysosomes or proteasomes

Emerging Targeted Protein Degradation Tools for Innovative Drug Discovery: from Classical PROTACs to the Novel and Beyond.

Advancing targeted protein degradation for cancer therapy

Exploring the target scope of KEAP1 E3 ligase-based PROTACs

Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15